PT2630146T - Sal tosilato de (8s,9r)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-di-hidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona cristalino - Google Patents

Sal tosilato de (8s,9r)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-di-hidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona cristalino

Info

Publication number
PT2630146T
PT2630146T PT117770057T PT11777005T PT2630146T PT 2630146 T PT2630146 T PT 2630146T PT 117770057 T PT117770057 T PT 117770057T PT 11777005 T PT11777005 T PT 11777005T PT 2630146 T PT2630146 T PT 2630146T
Authority
PT
Portugal
Prior art keywords
phtalazin
crystaline
pyrido
triazol
fluorophenyl
Prior art date
Application number
PT117770057T
Other languages
English (en)
Original Assignee
Medivation Tech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44903424&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2630146(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivation Tech Llc filed Critical Medivation Tech Llc
Publication of PT2630146T publication Critical patent/PT2630146T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
PT117770057T 2010-10-21 2011-10-20 Sal tosilato de (8s,9r)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-di-hidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona cristalino PT2630146T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40547610P 2010-10-21 2010-10-21

Publications (1)

Publication Number Publication Date
PT2630146T true PT2630146T (pt) 2020-07-20

Family

ID=44903424

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117770057T PT2630146T (pt) 2010-10-21 2011-10-20 Sal tosilato de (8s,9r)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-di-hidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona cristalino

Country Status (24)

Country Link
US (3) US8735392B2 (pt)
EP (2) EP2630146B1 (pt)
JP (5) JP2013540158A (pt)
KR (4) KR20140009181A (pt)
CN (1) CN103282365B (pt)
AR (1) AR083502A1 (pt)
AU (2) AU2011317040B2 (pt)
BR (1) BR112013009117A2 (pt)
CA (1) CA2814581C (pt)
CY (1) CY1123356T1 (pt)
DK (1) DK2630146T3 (pt)
ES (1) ES2816600T3 (pt)
HU (1) HUE051535T2 (pt)
IL (2) IL225789B (pt)
MX (1) MX362563B (pt)
NZ (1) NZ609490A (pt)
PL (1) PL2630146T3 (pt)
PT (1) PT2630146T (pt)
RU (1) RU2598606C3 (pt)
SG (2) SG189939A1 (pt)
SI (1) SI2630146T1 (pt)
TW (2) TWI557123B (pt)
WO (1) WO2012054698A1 (pt)
ZA (1) ZA201302810B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2625817T3 (es) 2008-08-06 2017-07-20 Medivation Technologies, Inc. Inhibidores de tipo Dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP)
US20120121515A1 (en) 2009-03-13 2012-05-17 Lenny Dang Methods and compositions for cell-proliferation-related disorders
ES2632954T3 (es) 2009-06-29 2017-09-18 Agios Pharmaceuticals, Inc. Derivados de quinolina-8-sulfonamida que tienen una actividad anticancerosa
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
JP5883397B2 (ja) 2010-02-03 2016-03-15 ビオマリン プハルマセウトイカル インコーポレイテッド Ｐｔｅｎ欠損に関連した疾患の治療におけるポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）のジヒドロピリドフタラジノン阻害剤の使用
KR101826652B1 (ko) * 2010-02-08 2018-02-07 메디베이션 테크놀로지즈, 인크. 디히드로피리도프탈라지논 유도체의 합성 방법
TWI557123B (zh) 2010-10-21 2016-11-11 梅迪維新技術公司 結晶型（８Ｓ，９Ｒ）－５－氟－８－（４－氟苯基）－９－（１－甲基－１Ｈ－１，２，４－***－５－基）－８，９－二氫－２Ｈ－吡啶并［４，３，２－ｄｅ］呔－３（７Ｈ）－酮甲苯磺酸鹽
SG194697A1 (en) 2011-05-03 2013-12-30 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
EP2742030B1 (de) * 2011-08-11 2016-07-27 Bayer Intellectual Property GmbH 1,2,4-triazolyl-substituierte ketoenole zum einsatz im pflanzenschutz
WO2013028495A1 (en) * 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
EP2906212A4 (en) 2012-10-15 2016-06-08 Agios Pharmaceuticals Inc THERAPEUTIC COMPOUNDS AND COMPOSITIONS
EP3019480B1 (en) 2013-07-11 2020-05-06 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CA2939082C (en) 2014-02-13 2022-06-07 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
ME03580B (me) 2014-02-13 2020-07-20 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
PL3116491T3 (pl) * 2014-03-14 2022-02-07 Les Laboratoires Servier Kompozycje farmaceutyczne związków terapeutycznie aktywnych
KR20240010105A (ko) * 2014-03-14 2024-01-23 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
AU2015296289B2 (en) * 2014-07-31 2020-02-27 Medivation Technologies Llc Coformer salts of (2S,3S)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them
TWI714567B (zh) 2015-04-03 2021-01-01 美商英塞特公司 作為lsd1抑制劑之雜環化合物
US11234976B2 (en) 2015-06-11 2022-02-01 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
CR20180152A (es) 2015-08-12 2018-08-09 Incyte Corp Sales de un inhibidor de lsd1
CA3216701A1 (en) 2015-10-15 2017-04-20 Les Laboratoires Servier Combination therapy for treating malignancies
US10653710B2 (en) 2015-10-15 2020-05-19 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
JP2018536700A (ja) * 2015-10-26 2018-12-13 メディヴェイション テクノロジーズ， エルエルシー Ｐａｒｐ阻害剤を用いる小細胞肺がんの治療
CA3236518A1 (en) 2016-02-29 2017-09-08 F. Hoffmann-La Roche Ag Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
RU2020113246A (ru) 2017-10-13 2021-11-15 Мерк Патент Гмбх Комбинация ингибитора parp и антагониста, связывающегося с осью pd-1
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
US11368702B2 (en) 2018-06-04 2022-06-21 Lg Electronics, Inc. Method and device for processing video signal by using affine motion prediction
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
US10942500B2 (en) * 2018-06-11 2021-03-09 Purdue Research Foundation System architecture and method of processing data therein
US10382772B1 (en) * 2018-07-02 2019-08-13 Tencent America LLC Method and apparatus for video coding
WO2020014700A1 (en) 2018-07-13 2020-01-16 Magic Leap, Inc. Systems and methods for display binocular deformation compensation
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
EP3876940A1 (en) 2018-11-05 2021-09-15 Pfizer Inc. Combinations for treating cancer
JP2023517044A (ja) 2020-03-09 2023-04-21 ファイザー・インク 融合タンパク質およびその使用
AU2021379314A1 (en) 2020-11-13 2023-06-15 Pfizer Inc. Talazoparib soft gelatin capsule dosage form
US20240052423A1 (en) 2020-12-07 2024-02-15 Pfizer Inc. Methods of identifying a tumor that is sensitive to treatment with talazoparib and methods of treatment thereof
JP2024510666A (ja) 2021-03-24 2024-03-08 ファイザー・インク Ｄｄｒ遺伝子変異転移性去勢感受性前立腺がんを処置するためのタラゾパリブおよび抗アンドロゲンの組合せ
WO2023131894A1 (en) 2022-01-08 2023-07-13 Pfizer Inc. Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
WO2023233295A1 (en) 2022-06-01 2023-12-07 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof
WO2024074959A1 (en) 2022-10-02 2024-04-11 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415504A (en) 1981-09-21 1983-11-15 Tanabe Seiyaku Co., Ltd. p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine
JPS58225065A (ja) 1982-06-21 1983-12-27 Nippon Shinyaku Co Ltd ２−キノロン誘導体
US5328905A (en) 1987-07-20 1994-07-12 Duphar International Research B.V. 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives
GB9505538D0 (en) 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
ID19155A (id) 1996-12-13 1998-06-18 Tanabe Seiyaku Co Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya
DE19727410A1 (de) 1997-06-27 1999-01-07 Hoechst Schering Agrevo Gmbh 3-(5-Tetrazolylcarbonyl)-2-chinolone und diese enthaltende nutzpflanzenschützende Mittel
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
TW430656B (en) 1997-12-03 2001-04-21 Dainippon Ink & Chemicals Quinolinone derivative, method for preparing the same, and anti-allergic agent
CA2332239A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
DE19921567A1 (de) 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
JP2001302669A (ja) 2000-04-18 2001-10-31 Meiji Seika Kaisha Ltd 三環性フタラジノン誘導体
JP2002284699A (ja) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
SE0102315D0 (sv) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
BR0307780A (pt) * 2002-02-19 2004-12-28 Ono Pharmaceutical Co Compostos derivados de piridazina fundida e medicamentos contendo os compostos como o ingrediente ativo
EP1340819A1 (en) 2002-02-28 2003-09-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Microsatellite markers
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
EP1400244A1 (en) 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
AU2003277674A1 (en) 2002-11-12 2004-06-03 Mochida Pharmaceutical Co., Ltd. Novel parp inhibitors
CA2517629C (en) * 2003-03-12 2011-07-12 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7268138B2 (en) 2003-05-28 2007-09-11 Mgi Gp, Inc. Compounds, methods and pharmaceutical compositions for inhibiting PARP
US20070197549A1 (en) 2004-02-18 2007-08-23 Astrazeneca Ab Tetrazole compounds and their use as metabotropic glutamate receptor antagonists
GB0612971D0 (en) 2006-06-30 2006-08-09 Angeletti P Ist Richerche Bio Therapeutic compounds
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
CN101675040A (zh) 2007-05-03 2010-03-17 辉瑞有限公司 作为钠通道调节剂的2-吡啶甲酰胺衍生物
WO2009024190A1 (en) 2007-08-22 2009-02-26 4Sc Ag Indolopyridines as inhibitors of the kinesin spindle protein (eg5 )
CN101998959B (zh) 2008-02-06 2013-08-28 生物马林药物股份有限公司 聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂
ES2625817T3 (es) 2008-08-06 2017-07-20 Medivation Technologies, Inc. Inhibidores de tipo Dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP)
BRPI0914556A2 (pt) 2008-08-12 2015-08-04 Boehringer Ingelheim Int Processo para a preparação de compostos de piperazina substituídos por cicloalquila
JP5883397B2 (ja) 2010-02-03 2016-03-15 ビオマリン プハルマセウトイカル インコーポレイテッド Ｐｔｅｎ欠損に関連した疾患の治療におけるポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）のジヒドロピリドフタラジノン阻害剤の使用
US20110190266A1 (en) 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
KR101826652B1 (ko) 2010-02-08 2018-02-07 메디베이션 테크놀로지즈, 인크. 디히드로피리도프탈라지논 유도체의 합성 방법
WO2011130661A1 (en) 2010-04-16 2011-10-20 Biomarin Pharmaceutical Inc. Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
WO2011140009A1 (en) 2010-05-04 2011-11-10 Biomarin Pharmaceutical Inc. Methods of using semi-synthetic glycopeptides as antibacterial agents
TWI557123B (zh) 2010-10-21 2016-11-11 梅迪維新技術公司 結晶型（８Ｓ，９Ｒ）－５－氟－８－（４－氟苯基）－９－（１－甲基－１Ｈ－１，２，４－***－５－基）－８，９－二氫－２Ｈ－吡啶并［４，３，２－ｄｅ］呔－３（７Ｈ）－酮甲苯磺酸鹽
WO2012166151A1 (en) 2011-06-03 2012-12-06 Biomarin Pharmaceutical Inc. Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml)
WO2013028495A1 (en) 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
US20130053365A1 (en) 2011-08-30 2013-02-28 Biomarin Pharmaceutical, Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
US20160280691A1 (en) 2013-11-07 2016-09-29 Biomarin Pharmaceutical Inc. Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes
AU2015296289B2 (en) 2014-07-31 2020-02-27 Medivation Technologies Llc Coformer salts of (2S,3S)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them

Also Published As

Publication number Publication date
SG189939A1 (en) 2013-06-28
ZA201302810B (en) 2014-06-25
KR20140009181A (ko) 2014-01-22
CN103282365A (zh) 2013-09-04
RU2598606C2 (ru) 2016-09-27
RU2598606C3 (ru) 2021-12-20
US20140228369A1 (en) 2014-08-14
MX362563B (es) 2019-01-25
KR20190120458A (ko) 2019-10-23
US20180009806A1 (en) 2018-01-11
JP2020169209A (ja) 2020-10-15
WO2012054698A1 (en) 2012-04-26
ES2816600T3 (es) 2021-04-05
AU2017201564B2 (en) 2019-05-09
EP2630146A1 (en) 2013-08-28
JP2019034951A (ja) 2019-03-07
CN103282365B (zh) 2017-12-29
IL271497A (en) 2020-02-27
TW201307345A (zh) 2013-02-16
EP2630146B1 (en) 2020-07-01
HUE051535T2 (hu) 2021-03-01
PL2630146T3 (pl) 2020-11-02
US8735392B2 (en) 2014-05-27
US20120129865A1 (en) 2012-05-24
MX2013004195A (es) 2013-07-22
CA2814581C (en) 2019-02-12
SI2630146T1 (sl) 2020-12-31
AU2011317040B2 (en) 2016-12-08
EP3757106A1 (en) 2020-12-30
KR20180069132A (ko) 2018-06-22
TWI557123B (zh) 2016-11-11
IL225789A0 (en) 2013-06-27
TWI643858B (zh) 2018-12-11
KR20210028747A (ko) 2021-03-12
US10189837B2 (en) 2019-01-29
BR112013009117A2 (pt) 2016-07-19
TW201713656A (en) 2017-04-16
AR083502A1 (es) 2013-02-27
SG10201710578TA (en) 2018-02-27
DK2630146T3 (da) 2020-08-10
AU2011317040A1 (en) 2013-05-09
NZ609490A (en) 2015-06-26
JP2017061526A (ja) 2017-03-30
JP2022140637A (ja) 2022-09-26
CY1123356T1 (el) 2021-12-31
CA2814581A1 (en) 2012-04-26
RU2013123036A (ru) 2014-11-27
IL225789B (en) 2019-12-31
JP2013540158A (ja) 2013-10-31
AU2017201564A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
IL271497A (en) Tosylate salt of (S8, R9)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-H1- 4,2,1-triazol-5-yl)-9,8-dihydro-H2 -Crystalline pyrido[2,3,4-de]phthalazine-3(H3)-one
ZA201209632B (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
EP2477648A4 (en) SYNERGISTIC ANTI-CD47 THERAPY FOR HEMATOLOGICAL CANCER
ZA201302271B (en) Controlled motorized brewing unit
IL223844A (en) History of indolysin, a process for their preparation and medical use
EP2656847A4 (en) CONJUGATE FOR PHOTODYNAMIC DIAGNOSIS OR THERAPY AND PREPARATION METHOD THEREOF
EP2619203A4 (en) TRICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND APPLICATIONS THEREOF
EP2578584A4 (en) ARYLAMINE DERIVATIVES OF PURINE, PROCESS FOR PREPARING THEM AND THEIR PHARMACEUTICAL USE
IL218490A0 (en) Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof
EP2549947A4 (en) COMPOSITE THREE DIMENSIONAL SURGICAL IMPLANT
EP2552833A4 (en) Surface-modified zeolites and methods for preparing the same
HK1175776A1 (en) 8-azabicyclo[3.2.1]octane-8-carboxamide derivative 8-[321]-8-
IL222080B (en) 6-alkyl-thieno[2,3-c]quinolin-4(5h)-one derivatives
IL220448A (en) Pyridine [3,2 - d] Pyrimidine - 7 (8h) - Their medical uses and uses
IL236808B (en) Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one
HK1185882A1 (en) Pyrazino[2,3-d]isoxazole derivative [23-d]
ZA201303580B (en) Oxazolo [5,4-b]pyridin-5-yl compounds and their use for the treatment of cancer
SI2477990T1 (sl) 5-fenil-pirazolopiridinski derivati, njihova priprava in terapevtska uporaba
IL226388A0 (en) New indolizine derivatives, their preparation and medical use
EP2621490A4 (en) PROPARGYL-TRIFLUOROMETHOXY-AMINO-BENZOTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF
AU2010902149A0 (en) Safe drink detector
AU2010900022A0 (en) Adjustable body stimulator
PL390377A1 (pl) Sposób i układ do wspomagania terapii resynchronizującej serca